11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Neuroinflammation in mouse models of Alzheimer's disease

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alzheimer's disease ( AD) is the most common type of neurocognitive disorder. Although both amyloid β peptide deposition and neurofibrillary tangle formation in the AD brain have been established as pathological hallmarks of the disease, many other factors contribute in a complex manner to the pathogenesis of AD before clinical symptoms of the disease become apparent. Longitudinal pathophysiological processes cause patients’ brains to exist in a state of chronic neuroinflammation, with glial cells acting as key regulators of the neuroinflammatory state. However, the detailed molecular and cellular mechanisms of glial function underlying AD pathogenesis remain elusive. Furthermore, recent studies have shown that peripheral inflammatory conditions affect glial cells in the brain through a process of neuroimmune communication. Such disease complexities make it difficult for the pathogenesis of AD to be understood, and impede the development of effective therapeutic strategies to combat the disease. Relevant AD animal models are thus likely to serve as a key resource to overcome many of these issues. Furthermore, as the pathogenesis of AD might be linked to conditions both within the brain as well as peripherally, it might become necessary for AD to be studied as a whole‐body disorder. The present review aimed to summarize insights regarding current AD research, and share perspectives for understanding glial function in the context of the pathogenesis of AD.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease

          The spreading of pathology within and between brain areas is a hallmark of neurodegenerative disorders. In patients with Alzheimer's disease, deposition of amyloid-β is accompanied by activation of the innate immune system and involves inflammasome-dependent formation of ASC specks in microglia. ASC specks released by microglia bind rapidly to amyloid-β and increase the formation of amyloid-β oligomers and aggregates, acting as an inflammation-driven cross-seed for amyloid-β pathology. Here we show that intrahippocampal injection of ASC specks resulted in spreading of amyloid-β pathology in transgenic double-mutant APPSwePSEN1dE9 mice. By contrast, homogenates from brains of APPSwePSEN1dE9 mice failed to induce seeding and spreading of amyloid-β pathology in ASC-deficient APPSwePSEN1dE9 mice. Moreover, co-application of an anti-ASC antibody blocked the increase in amyloid-β pathology in APPSwePSEN1dE9 mice. These findings support the concept that inflammasome activation is connected to seeding and spreading of amyloid-β pathology in patients with Alzheimer's disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            APP mouse models for Alzheimer's disease preclinical studies

            Abstract Animal models of human diseases that accurately recapitulate clinical pathology are indispensable for understanding molecular mechanisms and advancing preclinical studies. The Alzheimer's disease (AD) research community has historically used first‐generation transgenic (Tg) mouse models that overexpress proteins linked to familial AD (FAD), mutant amyloid precursor protein (APP), or APP and presenilin (PS). These mice exhibit AD pathology, but the overexpression paradigm may cause additional phenotypes unrelated to AD. Second‐generation mouse models contain humanized sequences and clinical mutations in the endogenous mouse App gene. These mice show Aβ accumulation without phenotypes related to overexpression but are not yet a clinical recapitulation of human AD. In this review, we evaluate different APP mouse models of AD, and review recent studies using the second‐generation mice. We advise AD researchers to consider the comparative strengths and limitations of each model against the scientific and therapeutic goal of a prospective preclinical study.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.

              Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, are inconsistent. We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line, in 1991. To detect new cases of dementia, follow-up screening was performed in 1993 and 1994 and again in 1997 through 1999. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine Hz-receptor antagonists, antihypertensive agents, and hypoglycemic agents. During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia. The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.
                Bookmark

                Author and article information

                Contributors
                takashi.saito.aa@riken.jp
                takaomi.saido@riken.jp
                Journal
                Clin Exp Neuroimmunol
                Clin Exp Neuroimmunol
                10.1111/(ISSN)1759-1961
                CEN3
                Clinical & Experimental Neuroimmunology
                John Wiley and Sons Inc. (Hoboken )
                1759-1961
                23 September 2018
                November 2018
                : 9
                : 4 ( doiID: 10.1111/cen3.2018.9.issue-4 )
                : 211-218
                Affiliations
                [ 1 ] RIKEN Center for Brain Science Laboratory for Proteolytic Neuroscience Wako Japan
                [ 2 ] Department of Neuroscience and Pathobiology Research Institute of Environmental Medicine Nagoya University Wako Japan
                Author notes
                [*] [* ] Correspondence

                Takashi Saito and Takaomi C. Saido, Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2‐1 Hirosawa, Wako‐city, Saitama 351‐0198, Japan.

                Tel: +81‐48‐462‐1111 (Ext. 7615)

                Fax: +81‐48‐467‐9716

                Emails: takashi.saito.aa@ 123456riken.jp , takaomi.saido@ 123456riken.jp

                Author information
                http://orcid.org/0000-0002-9659-9251
                http://orcid.org/0000-0003-1970-6903
                Article
                CEN312475
                10.1111/cen3.12475
                6282739
                30546389
                10fb5670-63ea-4066-a708-3add79b83d44
                © 2018 The Authors. Clinical and Experimental Neuroimmunology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society for Neuroimmunology

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 01 August 2018
                : 19 August 2018
                Page count
                Figures: 2, Tables: 0, Pages: 8, Words: 5065
                Funding
                Funded by: AMED (Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS)
                Award ID: JP18dm027001
                Award ID: JP18dm0107070h0003
                Funded by: Cell Science Research Foundation
                Funded by: Aging Project of RIKEN
                Funded by: RIKEN Center for Brain Science
                Funded by: Ministry of Education, Culture, Sports, Science and Technology
                Award ID: 26290019
                Categories
                Review Article
                Focused Review Series planned by Koji Yamanaka: Neuroinflammation in neurodegeneration and dementia
                Review Articles
                Custom metadata
                2.0
                cen312475
                November 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.3 mode:remove_FC converted:06.12.2018

                alzheimer's disease,glial cell,mouse model,neuroimmune communication,neuroinflammation

                Comments

                Comment on this article